Prosecution Insights
Last updated: July 05, 2026
Application No. 18/280,388

Method for preparing 2-hydroxy-4-methylthiobutyronitrile or the selenium equivalent thereof, and applications

Non-Final OA §102§103
Filed
Sep 05, 2023
Priority
Mar 04, 2021 — FR FR2102123 +1 more
Examiner
SHTERENGARTS, SAMANTHA L
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Adisseo France S A S
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
87%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1336 granted / 1684 resolved
+19.3% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
73 currently pending
Career history
1720
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
24.1%
-15.9% vs TC avg
§112
22.2%
-17.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1684 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority 2. The instant application is a national stage entry of PCT/FR2022/050388, filed March 4, 2022. 3. Acknowledgment is made of applicant's claim for foreign priority under 35 U.S.C. 119(a)-(d) by application no. FR2102123 filed in the French Patent Office on March 4, 2021, which papers have been placed of record in the file. Information Disclosure Statement 4. The information disclosure statements (IDS) submitted on September 5, 2023; October 2, 2025; November 24, 2025; and December 31, 2025 were in compliance with the provisions of 37 CFR 1.97 and 37 CFR 1.98. The IDS documents were considered. A signed copy of each form 1449 is enclosed herewith. Election/Restrictions 5. Applicant’s election without traverse of Group I in the reply filed on February 5, 2026 is acknowledged. Status of the Claims 6. Claims 1-15 are pending in the instant application. Claims 11-15 are withdrawn for being drawn to a non-elected invention. Claims 1-10 are under consideration herein. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. 7. The following is a quotation of the appropriate paragraphs of pre-AIA 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. 8. Claims 1-3 and 6-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by JP4517486B2. JP4517486B2 teaches a method for preparing HMTBN from MTP and HCN with a molar ratio of HCN:MTP of 1:05:1 and in the presence of potassium carbonate. The pH is adjusted to 7.9 and then reaction medium is acidified by lowering to a pH of 1.33 by adding sulphuric acid (see translation, abstract, and table) and working Examples 1-4. See [0011] for pH and distillation limitations of instant claims and [0009] for limitations regarding the continuous carrying out of the method. Claim Rejections - 35 USC § 103 9. Claim(s) 1-10 is/are rejected under 35 U.S.C. 103 as being unpatentable over JP4517486B2 in view of CN109912472A. JP4517486B2 teaches a method for preparing HMTBN from MTP and HCN with a molar ratio of HCN:MTP of 1:05:1 and in the presence of potassium carbonate. The pH is adjusted to 7.9 and then reaction medium is acidified by lowering to a pH of 1.33 by adding sulphuric acid (see translation, abstract, and table) and working Examples 1-4. See [0011] for pH and distillation limitations of instant claims and [0009] for limitations regarding the continuous carrying out of the method. JP4517486B2 does not specifically tech the temperature range of instant claim 4 or the limitations of instant claim 5. CN109912472A teaches a method for preparing HMTBN from MTP and HCN with a molar ratio of HCN:MTP of 1:001 to 1. The process comprises microchannel reaction of MTP with HCN under catalysis of catalyst (citric acid-sodium citrate buffer solution, acetic acid-sodium acetate buffer solution, etc.) at 30-70° and 0.05-0.5 MPa for 0.5-10 min. The process has shortened reaction time, reduced generation of byproducts, high product yield and low cost. See MPEP 2144.05(I): Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955). With respect to this difference, MPEP 2141 states, "The key to supporting any rejection under 35 U.S.C. 103 is the clear articulation of the reason(s) why the claimed invention would have been obvious. The Supreme Court in KSR noted that the analysis supporting a rejection under 35 U.S.C. 103 should be made explicit. The Court quoting In re Kahn, 441 F.3d 977, 988, 78 USPQ2d 1329, 1336 (Fed. Cir. 2006), stated that "[R]ejections on obviousness cannot be sustained by mere conclusatory statements; instead, there must be some articulated reasoning with some rational underpinning to support the legal conclusion of obviousness.’" KSR, 550 U.S. at ___, 82 USPQ2d at 1396. Exemplary rationales that may support a conclusion of obviousness include: (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) " Obvious to try " - choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention." Based on the teachings of the MPEP and KSR above, by employing the rationale in A and F above, it would have been obvious for one of ordinary skill in the art to make the aforementioned modifications and arrive at the presently claimed invention. If a prima facie case of obviousness is established, the burden shifts to the applicant to come forward with arguments and/or evidence to rebut the prima facie case. See, e.g., In re Dillon, 919 F.2d 688, 692, 16 USPQ2d 1897, 1901 (Fed. Cir. 1990). Rebuttal evidence and arguments can be presented in the specification, In re Soni, 54 F.3d 746, 750, 34 USPQ2d 1684, 1687 (Fed. Cir. 1995), by counsel, In re Chu, 66 F.3d 292, 299, 36 USPQ2d 1089, 1094-95 (Fed. Cir. 1995), or by way of an affidavit or declaration under 37 CFR 1.132, e.g., Soni, 54 F.3d at 750, 34 USPQ2d at 1687; In re Piasecki, 745 F.2d 1468, 1474, 223 USPQ 785, 789-90 (Fed. Cir. 1984). However, arguments of counsel cannot take the place of factually supported objective evidence. See, e.g., In re Huang, 100 F.3d 135, 139-40, 40 USPQ2d 1685, 1689 (Fed. Cir. 1996); In re De Blauwe, 736 F.2d 699, 705, 222 USPQ 191, 196 (Fed. Cir. 1984). See MPEP 2145. Please note that if Applicant intends to rely on unexpected or unforeseen results, attention is invited to MPEP 716. Absent clear, convincing, side-by-side data demonstrating unobviousness vis-à-vis the prior art commensurate with the scope of protection sought, the claims are considered prima facie obviousness. Conclusion 10. No claims are allowed. 11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samantha Shterengarts whose telephone number is (571)270-5316. The examiner can normally be reached on Monday thru Thursday 9-6pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Mr. Adam Milligan can be reached on 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMANTHA L SHTERENGARTS/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Sep 05, 2023
Application Filed
May 28, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12655106
HDAC6 INHIBITORS AND USES THEREOF
2y 10m to grant Granted Jun 16, 2026
Patent 12617759
MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF
4y 0m to grant Granted May 05, 2026
Patent 12606529
SULFUR AND AMIDE TROPOLONE INHIBITORS OF NUCLEOTIDYL TRANSFERASES AND USES THEREFOR
4y 5m to grant Granted Apr 21, 2026
Patent 12606526
SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF
2y 9m to grant Granted Apr 21, 2026
Patent 12600723
TETRACYCLIC COMPOUNDS AS DGK INHIBITORS
2y 9m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
87%
With Interview (+8.0%)
2y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1684 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month